Welcome to LookChem.com Sign In|Join Free
  • or
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1,5-dimethyl-pyrazole-3-carboxamide trifluoroacetate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1361031-15-3

Post Buying Request

1361031-15-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1361031-15-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1361031-15-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,6,1,0,3 and 1 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1361031-15:
(9*1)+(8*3)+(7*6)+(6*1)+(5*0)+(4*3)+(3*1)+(2*1)+(1*5)=103
103 % 10 = 3
So 1361031-15-3 is a valid CAS Registry Number.

1361031-15-3Downstream Products

1361031-15-3Relevant academic research and scientific papers

Pharmaceutically active compounds as Axl inhibitors

-

Paragraph 0062, (2013/03/26)

The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides of general formula (I): and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.

PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS

-

Page/Page column 80, (2012/03/26)

The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides of general formula (I): and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1361031-15-3